JP2021515017A5 - - Google Patents
Info
- Publication number
- JP2021515017A5 JP2021515017A5 JP2020546443A JP2020546443A JP2021515017A5 JP 2021515017 A5 JP2021515017 A5 JP 2021515017A5 JP 2020546443 A JP2020546443 A JP 2020546443A JP 2020546443 A JP2020546443 A JP 2020546443A JP 2021515017 A5 JP2021515017 A5 JP 2021515017A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally
- subject
- antibody
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024002970A JP2024045219A (ja) | 2018-03-07 | 2024-01-12 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639891P | 2018-03-07 | 2018-03-07 | |
| US62/639,891 | 2018-03-07 | ||
| US201862736343P | 2018-09-25 | 2018-09-25 | |
| US62/736,343 | 2018-09-25 | ||
| PCT/US2019/021024 WO2019173523A1 (en) | 2018-03-07 | 2019-03-06 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002970A Division JP2024045219A (ja) | 2018-03-07 | 2024-01-12 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515017A JP2021515017A (ja) | 2021-06-17 |
| JP2021515017A5 true JP2021515017A5 (enExample) | 2022-03-14 |
| JP7471227B2 JP7471227B2 (ja) | 2024-04-19 |
Family
ID=67845742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546443A Active JP7471227B2 (ja) | 2018-03-07 | 2019-03-06 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
| JP2024002970A Pending JP2024045219A (ja) | 2018-03-07 | 2024-01-12 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002970A Pending JP2024045219A (ja) | 2018-03-07 | 2024-01-12 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210030888A1 (enExample) |
| EP (1) | EP3762032A4 (enExample) |
| JP (2) | JP7471227B2 (enExample) |
| KR (1) | KR20200130356A (enExample) |
| CN (1) | CN112105388A (enExample) |
| AU (1) | AU2019231696B2 (enExample) |
| BR (1) | BR112020018092A2 (enExample) |
| CA (1) | CA3091217A1 (enExample) |
| IL (1) | IL276768A (enExample) |
| MX (1) | MX2020008613A (enExample) |
| SG (1) | SG11202007865VA (enExample) |
| UA (1) | UA129351C2 (enExample) |
| WO (1) | WO2019173523A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| JP7460608B2 (ja) | 2018-05-07 | 2024-04-02 | ジェンマブ エー／エス | 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| MX2023005930A (es) * | 2020-11-26 | 2023-05-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon. |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| CN114569734B (zh) * | 2022-01-17 | 2023-08-29 | 北京化工大学 | 一种基于还原敏感聚合物递送阳离子铂药的纳米粒的制备方法 |
| JP2025515166A (ja) * | 2022-05-06 | 2025-05-13 | ジェンマブ エー／エス | 抗組織因子抗体－薬物コンジュゲートを用いたがんの治療方法 |
| WO2024067864A1 (en) * | 2022-09-30 | 2024-04-04 | Shanghai Junshi Biosciences Co., Ltd. | Anti-lair1 antibodies and their uses |
| CA3266848A1 (en) * | 2022-10-19 | 2024-04-25 | Multitude Therapeutics Inc. | Antibodies, antibody-drug conjugates, preparations and uses thereof |
| CN122295131A (zh) * | 2023-10-19 | 2026-06-26 | 赛特瑞恩股份有限公司 | 包含喜树碱衍生物的抗组织因子抗体-药物缀合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA109633C2 (uk) * | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| JP6055404B2 (ja) * | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| HUE055109T2 (hu) * | 2015-09-11 | 2021-11-29 | Genmab As | Adagolási rendek TF elleni antitest és gyógyszer konjugátumaihoz |
-
2019
- 2019-03-06 SG SG11202007865VA patent/SG11202007865VA/en unknown
- 2019-03-06 KR KR1020207028401A patent/KR20200130356A/ko not_active Ceased
- 2019-03-06 US US16/978,539 patent/US20210030888A1/en active Pending
- 2019-03-06 AU AU2019231696A patent/AU2019231696B2/en active Active
- 2019-03-06 MX MX2020008613A patent/MX2020008613A/es unknown
- 2019-03-06 CN CN201980031334.6A patent/CN112105388A/zh active Pending
- 2019-03-06 JP JP2020546443A patent/JP7471227B2/ja active Active
- 2019-03-06 BR BR112020018092-0A patent/BR112020018092A2/pt unknown
- 2019-03-06 WO PCT/US2019/021024 patent/WO2019173523A1/en not_active Ceased
- 2019-03-06 EP EP19764722.5A patent/EP3762032A4/en active Pending
- 2019-03-06 CA CA3091217A patent/CA3091217A1/en active Pending
- 2019-03-06 UA UAA202005163A patent/UA129351C2/uk unknown
-
2020
- 2020-08-17 IL IL276768A patent/IL276768A/en unknown
-
2024
- 2024-01-12 JP JP2024002970A patent/JP2024045219A/ja active Pending
-
2026
- 2026-01-30 US US19/465,882 patent/US20260151500A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518394A5 (enExample) | ||
| JP2021501776A5 (enExample) | ||
| JP2021523233A5 (enExample) | ||
| JP2021523158A5 (enExample) | ||
| JP2022513386A5 (enExample) | ||
| JP2021534165A5 (enExample) | ||
| JP7471227B2 (ja) | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 | |
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2023500888A5 (enExample) | ||
| US20190030178A1 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
| JP2022541591A5 (enExample) | ||
| JP2023500697A5 (enExample) | ||
| IL278400B2 (en) | Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2022544227A5 (enExample) | ||
| JP2025501978A5 (enExample) | ||
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2024519907A (ja) | 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用 | |
| CN112043832A (zh) | 用于联合治疗胃癌的喹啉类化合物 | |
| WO2025162287A1 (zh) | 抗her2抗体药物偶联物治疗肠癌的用途 | |
| WO2024183643A1 (zh) | 含抗tim-3抗体的药物组合 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| WO2024051670A1 (zh) | 结合tim-3的抗体与结合pd-1的抗体的药物组合 | |
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 |